Purdue’s Pediatric OxyContin Trial to Update Label Would Snag Six-Month Patent Extension
Purdue Pharma is denying reports it plans to seek FDA approval for pediatric OxyContin, despite an ongoing clinical trial studying the painkiller in children ages six to 16.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.